EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo

Fan Fan, Susmita Ghosh, Reid Powell, Jason Roszik, Yongsun Park, Mary Sobieski, Alexey Sorokin, Clifford Stephan iD, Scott Kopetz, Lee M Ellis, Rajat Bhattacharya iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Fan Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, DOD Peer Reviewed Cancer Research Program, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concentrated on targeting MEK, a downstream mediator of RAS. However, targeting MEK as single-agent therapy is ineffective in patients with mCRC. We hypothesize that combining a MEK inhibitor with other agents can enhance the efficacy of MEK targeting in mCRC. Unbiased high-throughput screening (HTS) was performed to identify drugs that enhance the efficacy of MEK inhibitors. HTS was performed with KRAS-mutated CRC cells using the MEK inhibitor trametinib as a “backbone” and two “clinically ready” compound libraries approved by the U.S. Food and Drug Administration or in clinical trials. HTS demonstrated that the combination of the SRC inhibitor dasatinib and trametinib was synergistic in CRC cells in vitro (MTT and colony formation assays). Analysis of markers for cell proliferation and apoptosis using fluorescence-activated cell sorting, reverse-phase protein array, or Western blotting demonstrated decreased cell proliferation and increased cell death when targeting both SRC and MEK as compared to single agents in multiple CRC cell lines. However, combining dasatinib and trametinib in vivo at doses in mice equivalent to doses used in humans failed to significantly enhance the antitumor activity of trametinib when compared to that of trametinib alone. These results underscore the importance of performing careful preclinical in vivo validation studies using clinically relevant doses as a prerequisite for translating in vitro findings to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsHumansMiceCell Line, TumorCell ProliferationDasatinibMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsPyridonesXenograft Model Antitumor AssaysGenes, src

Substanzen

DasatinibMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Pyridones

Autor:innen und Institutionen

  • Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
  • Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, College Station, Texas, United States of America.
  • Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
  • Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.
  • Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America.

ORCID-Profile: Clifford Stephan, Rajat Bhattacharya

Förderung

  • NCI NIH HHS
  • DOD Peer Reviewed Cancer Research Program
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Fan, F., Ghosh, S., Powell, R., Roszik, J., Park, Y., Sobieski, M., Sorokin, A., Stephan, C., Kopetz, S., Ellis, L. M., & Bhattacharya, R. (2023). Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLOS ONE. https://doi.org/10.1371/journal.pone.0281063

Vancouver

Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, et al. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLOS ONE. 2023. doi:10.1371/journal.pone.0281063

BibTeX
@article{Fan2023,
  author = {Fan, Fan and Ghosh, Susmita and Powell, Reid and Roszik, Jason and Park, Yongsun and Sobieski, Mary and Sorokin, Alexey and Stephan, Clifford and Kopetz, Scott and Ellis, Lee M and Bhattacharya, Rajat},
  title = {Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281063}
}
Kostenlos starten →